Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer
Status:
Not yet recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
This study is a randomized, open-label, controlled, multi-center Phase III clinical study,
aimed to evaluate the efficacy and safety of camrelizumab combined with famitinib malate
versus platinum-based chemotherapy in the treatment of recurrent/metastatic cervical cancer.
All enrolled patients will be randomly divided into 2 groups and continuously treated until
any event that meets the criteria for end of the clinical trial.